Agency for Science, Technology and Research

Immune System Therapeutics Ltd

Singapore Health Services Pte Ltd

Boon Hwa Andre Choo

Robert Lindsay Raison

Rosanne Dorothy Dunn

Mei Yee Vanessa Ding

Wey Jia Fong

Jiyun Zheng

Jodhbir Singh Mehta

Chui Ping Angela Chin

Gary Peh

Vai Tak Victor Wong

An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fuc&#x3b1;1-2Gal&#x3b2;1-3GlcNAc&#x3b2;1-3Gal&#x3b2;1 or Fuc&#x3b1;1-2Gal&#x3b2;1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.

Cytotoxic antibody

The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, therapeutic use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.

Anti-AXL tyrosine kinase receptor antibodies and uses thereof

An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fuc&#x3b1;1-2Gal&#x3b2;1-3GlcNAc1-3Gal&#x3b2;1 or Fuc&#x3b1;1-2Gal&#x3b2;1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.

This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal endothelial cells from a mixture of cell.

Enrichment and characterization of human corneal endothelial cells (hCENC) with novel monoclonal antibody

The disclosure relates to novel markers of pluripotent stem cells and uses thereof, and particularly, though not exclusively, to antibody molecules based on fragments of mAb84 which bind to undifferentiated pluripotent stem cells via podocalyxin-like protein-1 (PODXL).

Podocalyxin-like-protein-1 binding antibody molecule

The disclosure relates to methods of binding and identifying undifferentiated pluripotent stem cells and particularly, although not exclusively, to use of binding moieties which bind to PHB on the surface of undifferentiated pluripotent stem cells, such as PHB-binding peptides, and to methods for depleting undifferentiated stem cells from a sample.

Use of markers of undifferentiated pluripotent stem cell

The disclosure relates to methods for screening candidate antibody molecules which bind to podocalyxin-like protein (PODXL) and/or to undifferentiated pluripotent stem cells and particularly, although not exclusively, to methods for identifying candidate cytotoxic antibody molecules.

Methods for identifying candidate cytotoxic antibody molecules

The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody.

Growing community of inventors

Singapore, Singapore

Boon Hwa Andre Choo